Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4031 - Outcomes of clinical testing for tumor BRAC1 and BRCA2 gene analysis for 354 patients: first experience with tumor companion diagnostic for PARP inhibitors


08 Oct 2016


Poster Display


Karen Copeland


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


K.L. Copeland1, S.B. Wehnelt2, L.E. Wange2, B. Anwald2, A. Weicht2, A. Pfeufer2

Author affiliations

  • 1 Medical Affairs, Myriad Genetics GmbH, 8050 - Zurich/CH
  • 2 Laboratory, Myriad GmbH, München/DE


Abstract 4031


Ovarian cancer patients with deficiencies in the DNA repair pathway have shown to have a higher probability to respond to PARP inhibitors. Pathogenic mutations in the genes BRCA1 and BRCA2 lead to defects in the DNA repair pathway. It has been shown that the prevalence of mutations in the BRCA genes is higher in the tumor cells than in germline. Thus, a tumor-based test could identify a higher number of potential responders than a germline test.


This study assessed 354 consecutive individuals undergoing BRCA1 and BRCA2 full sequencing and large rearrangement analysis of DNA derived from FFPE tumor tissue in a DAkkS accredited laboratory in Munich, Germany from Jan 2015 through April 2016. The tumor-based BRCA test consists of sequencing and large rearrangement analyses of the BRCA1 and BRCA2 genes using next generation sequencing (NGS). The large rearrangements are detected by NGS dosage analysis to determine copy number abnormalities indicative of deletion or duplication mutations.


Out of the 354 analyzed samples, 93 (26,5%) tested positive for a laboratory classified pathogenic mutation; 57 were found in BRCA1 and 37 in BRCA2. One specimen contained a pathogenic mutation in both BRCA1 and BRCA2. Due to different quality and age of the tumor samples, large rearrangement analysis could not be completed in 24 cases (6,8%). VUS rate in the analyzed tumors was 4.2%. Of the pathogenic mutations detected, 93,6% were sequencing variants and 6,4% were large rearrangements. Overall cancellation rate due to insufficient tumor, insufficient DNA, incorrect tumor type or other cancellation reasons is less than 9% in the observed timespan of 16 months.


The current study demonstrates that a robust diagnostic platform can detect BRCA-related mutations in ovarian tumors. While the quality of specimens received into a commercial laboratory is quite variable, a positive rate of over 26% and an overall success rate (result generated) of over 91% indicates that tumor BRCA testing should be considered for ovarian cancer patients. In addition, a small but significant number of large rearrangements indicates that tumor BRCA testing should include dosage analysis for large rearrangements.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Myriad GmbH


Myriad GmbH


K.L. Copeland: Employee of Myriad Genetics GmbH including stock ownership. S.B. Wehnelt, L.E. Wange, B. Anwald, A. Weicht, A. Pfeufer: Myriad Employee.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings